Open Access Open Access  Restricted Access Subscription or Fee Access

Buprenorphine not a silver bullet but an opioid of choice for chronic pain

Mellar P. Davis, MD, FCCP, FAAHPM, Jeffrey Fudin, PharmD, FACCP, FASHP, FFSMB




buprenorphine, sustained-release

Full Text:



Coplan PM, Cepeda MS, Petronis KR, et al.: Postmarketing studies program to assess the risks and benefits of long-term use of extended-release/long-acting opioids among chronic pain patients. Postgrad Med. 2020; 132(1): 44-51.

Cone EJ, DePriest AZ, Gordon A, et al.: Risks and responsibilities in prescribing opioids for chronic noncancer pain, part 2: Best practices. Postgrad Med. 2014; 126(7): 129-138.

Dowell D, Haegerich TM: Using the CDC Guideline and Tools for Opioid Prescribing in Patients with Chronic Pain. Am Fam Physician. 2016; 93(12): 970-972.

Iacobellis A, Seripa D, Palmieri O, et al.: Efficacy and Safety of Long-Term Administration of Tapentadol in Relieving Chronic Pancreatitis Pain. Pain Med. 2017; 18(4): 815-817.

Howard RF, Radic T, Sohns M, et al.: Tapentadol Prolonged Release for Long-Term Treatment of Pain in Children. J Pain Res. 2020; 13: 3157-3170.

Davis MP, Mehta Z: Opioids and Chronic Pain: Where Is the Balance? Curr Oncol Rep. 2016; 18(12): 71.

Bialas P, Maier C, Klose P, et al.: Efficacy and harms of long-term opioid therapy in chronic non-cancer pain: Systematic review and meta-analysis of open-label extension trials with a study duration >/=26 weeks. Eur J Pain. 2020; 24(2): 265-278.

Heit HA, Covington E, Good PM: Dear DEA. Pain Med. 2004; 5(3): 303-308.

Chang Y, Moody DE: Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett. 2009; 3(2): 101-107.

Huang W, Moody DE, McCance-Katz EF: The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. Ther Drug Monit. 2006; 28(2): 245-251.

Picard N, Cresteil T, Djebli N, et al.: In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005; 33(5): 689-695.

Ohtani M, Kotaki H, Sawada Y, et al.: Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther. 1995; 272(2): 505-510.

Tournier N, Chevillard L, Megarbane B, Pet al.: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010; 13(7): 905-915.

Alhaddad H, Cisternino S, Decleves X, et al.: Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the bloodbrain barrier in mice. Crit Care Med. 2012; 40(12): 3215-3223.

Megarbane B, Hreiche R, Pirnay S, et al.: Does high-dose buprenorphine cause respiratory depression?: Possible mechanisms and therapeutic consequences. Toxicological Reviews. 2006; 25(2): 79-85.

Megarbane B, Marie N, Pirnay S, et al.: Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol. 2006; 212(3): 256-267.

Middleton LS, Nuzzo PA, Lofwall MR, et al.: The pharmacodynamics and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011; 106(8): 1460-1473.

Le Rouzic V, Narayan A, Hunkle A, et al.: Pharmacological Characterization of Levorphanol, a G-Protein Biased Opioid Analgesic. Anesth Analg. 2019; 128(2): 365-373.

Lu Z, Xu J, Xu M, et al.: Truncated mu-Opioid Receptors With 6 Transmembrane Domains Are Essential for Opioid Analgesia. Anesth Analg. 2018; 126(3): 1050-1057.

Grinnell SG, Ansonoff M, Marrone GF, et al.: Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants. Synapse. 2016; 70(10): 395-407.

Marrone GF, Majumdar S, Pasternak GW: Radioligand Binding Assay for an Exon 11-Associated Mu Opioid Receptor Target. Methods Mol Biol. 2015; 1335: 241-249.

Grinnell SG, Majumdar S, Narayan A, et al.: Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA. J Pharmacol Exp Ther. 2014; 350(3): 710-718.

Majumdar S, Subrath J, Le Rouzic V, et al.: Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated mu opioid receptor (MOR-1) splice variants. J Med Chem. 2012; 55(14): 6352-6362.

Abbadie C, Pan YX, Pasternak GW: Immunohistochemical study of the expression of exon11-containing mu opioid receptor variants in mouse brain. Neuroscience. 2004; 127(2): 419-430.

White LD, Hodge A, Vlok R, et al.: Efficacy and adverse effects of buprenorphine in acute pain management: Systematic review and meta-analysis of randomised controlled trials. Br J Anaesth. 2018; 120(4): 668-678.

Aiyer R, Gulati A, Gungor S, et al.: Treatment of Chronic Pain With Various Buprenorphine Formulations: A Systematic Review of Clinical Studies. Anesth Analg. 2018; 127(2): 529-538.

Wolff RF, Reid K, di Nisio M, et al.: Systematic review of adverse events of buprenorphine patch versus fentanyl patch in patients with chronic moderate-to-severe pain. Pain Manag. 2012; 2(4): 351-362.

Wolff RF, Aune D, Truyers C, et al.: Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin. 2012; 28(5): 833-845.

van Dam CJ, Algera MH, Olofsen E, et al.: Opioid utility function: Methods and implications. Ann Palliat Med. 2020; 9(2): 528-536.

Boom M, Niesters M, Sarton E, et al.: Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des. 2012; 18(37): 5994-6004.

Yassen A, Olofsen E, van Dorp E, et al.: Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone: A study in healthy volunteers. Clin Pharmacokinet. 2007; 46(11): 965-980.

Yassen A, Olofsen E, Kan J, et al.: Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res. 2008; 25(1): 183-193.

Yassen A, Olofsen E, Kan J, et al.: Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. Clin Pharmacokinet. 2007; 46(5): 433-447.

Yassen A, Olofsen E, Romberg R, et al.: Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology. 2006; 104(6): 1232-1242.

Dahan A, Yassen A, Romberg R, et al.: Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006; 96(5): 627-632.

Dahan A, Yassen A, Bijl H, et al.: Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005; 94(6): 825-834.

Yassen A, Olofsen E, Dahan A, et al.: Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: Role of receptor equilibration kinetics. J Pharmacol Exp Ther. 2005; 313(3): 1136-1149.

Dinges HC, Otto S, Stay DK, et al.: Side Effect Rates of Opioids in Equianalgesic Doses via Intravenous Patient-Controlled Analgesia: A Systematic Review and Network Metaanalysis. Anesth Analg. 2019; 129(4): 1153-1162.

Lazaridou A, Paschali M, Edwards RR, et al.: Is Buprenorphine Effective for Chronic Pain? A Systematic Review and Meta-analysis. Pain Med. 2020; 21(12): 3691-3699.

Urits I, Pham C, Swanson D, et al.: The utilization of buprenorphine in chronic pain. Best Pract Res Clin Anaesthesiol. 2020; 34(3): 355-368.

Brown SM, Holtzman M, Kim T, et al.: Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology. 2011; 115(6): 1251-1260.



  • There are currently no refbacks.